Association between scleroderma, renal cell carcinoma and membranous nephropathy

Clinical Nephrology

Volumn 71, Issue 1, 2009, Pages 63-68

  Nunez, S ^a,b   Konstantinov, K N ^a,b   Sevilla, K S ^b   Hartshorne, M F ^b   Williams, W L ^c   Gibel, L J ^c   Tzamaloukas, Antonios H ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Membranous nephropathy; Renal cell carcinoma; Scleroderma

Indexed keywords

AMLODIPINE; CAPTOPRIL; CREATININE; LEVOTHYROXINE; LISINOPRIL; LOSARTAN; MULTIVITAMIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEPRAZOLE; PENICILLAMINE; PREDNISONE; SEVELAMER;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; HEARTBURN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTHERMIC THERAPY; KIDNEY CARCINOMA; KIDNEY FUNCTION TEST; LABORATORY TEST; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHRECTOMY; NEPHROTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PROTEINURIA; RAYNAUD PHENOMENON; SCLERODERMA; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; SYSTEMIC SCLEROSIS;

CARCINOMA, RENAL CELL; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 63249133613     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71063     Document Type: Article

References (25)

1. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993; 36: 460-464.
2. Andrade LE, Chan EK, Peebles CL, Tan EM. Two major autoantigen-antibody systems of the mitotic spindle apparatus. Arthritis Rheum. 1996; 39: 1643-1653.
3. Bielefeld P, Meyer P, Caillot D, Dalac D, Dalac S, Camus P, Tavernier C, Couillaut G, Chalopin JM, Besancenot JF. Sclerodermie systemique et cancers: 21 observations et revue de la literature. Rev Med Interne. 1996; 17: 810-813.
4. Bouros D, Kostas H, Labrakis H, Zeibecoglou K. Association of malignancy with disease causing interstitial pulmonary changes. Chest. 2002; 121: 1278-1289.
5. Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis in cancer. Mol Cell Proteomics. 2006; 5: 1745-1759.
6. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma. Arthr Rheum. 2005; 52: 2415-2424.
7. Derk CT. Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol. 2007; 26: 1615-1619.
8. Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: the Mayo Clinic experience. Int J Radiation Oncology Biol Phys. 2007; 67: 559-567.
9. Heptinstall RH. Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and systemic scleroderma (progressive systemic sclerosis). In: Heptinstall RH (ed). Pathology of the Kidney, 3rd edition. Boston: Little, Brown and Co; 1983. pp. 907-991.
10. Herrera-Esparza R, Avalos-Diaz E, Barbosa-Cisneros O. Anti-NuMA antibodies: an uncommon specificity in scleroderma sera. Rev Rhum Engl Ed. 1999; 66: 315-318.
11. Hill CL, Nguyen A-M, Roder D, Roberts-Thompson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis. 2003; 62: 728-731.
12. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Brit J Rheumatol. 1998; 37: 750-755.
13. Kammerer S, Roth RB, Hoyal C, Reneland R, Marnellos G, Kiechle M, Scwarz-Boeger U, Griffiths LR, Ebner F, Rehbock J, Cantor CR, Nelson MR, Braun A. Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility. PNAS. 2005; 102: 2004-2009.
14. Konstantinov K, von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest. 1996; 98: 1888-1896.
15. Kuwana M, Fuji T, Mimori T, Kburaki J. Enhancement of anti DNA topoisomerase autoantibody response after lung cancer in patients with systemic sclerosis: A report of two cases. Arthritis Rheum. 1996; 39: 686-691.
16. Lyderson BK, Pettyjohn DE. Human-specific nuclear protein that associates with the polar region of the mitotic apparatus: distribution in a human/hamster hybrid cell. Cell. 1980; 22: 489-499.
17. Parry RG, Mason JC, Marley NJE. Membranous nephritis in a patient with scleroderma: a case report. Nephrol Dial Transplant. 1996; 11: 363-364.
18. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis. 2007; 66: 551-553.
19. Richter VW, Justus J. Sklerodermiformes paraneoplastisches Syndrom bei einem Nierenkarzinom. Z Gezamte Inn Med. 1978; 33: 193-195.
20. Roumm AD, Medsger TA. Cancer in systemic sclerosis: An epidemiologic study. Arthritis Rheum 1993; 36: 460-464.
21. Simeon CP, Armadans L, Fonollosa V. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology. 2003; 42: 71-75
22. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest. 2001; 108: 1411-1415.
23. Togawa A, Yamamoto T, Suzuki H, Watanabe K, Matsui K, Nagase M, Hishida A. Membranous glomerulo-nephritis associated with renal cell carcinoma: failure to detect a nephritogenic tumor antigen. Nephron. 2002; 90: 219-221.
24. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat Genet. 1997; 17: 109-113.
25. Wenzel J, Simeon CP, Armadan L, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology. 2003; 42: 71-75.